Trial Profile

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Antineoplastics; Atezolizumab; Durvalumab; Nivolumab; Pembrolizumab; Valaciclovir
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Advantagene; Candel Therapeutics

Most Recent Events

17 Mar 2026 Results published in the Candel Therapeutics Media Release
13 Nov 2025 According to a Candel Therapeutics media release, updated long-term survivors data expected in Q1 2026
03 Oct 2025 According to a Candel Therapeutics media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com